Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study Group.

Eur J Neurol · 2025 · PMC12351124 · PMID 40808545

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

quite significantno p-value reported

Likewise, a quite significant percentage of previously responsive CM patients (27; 31%) remained with response rates of < 30% in MHD reduction, resulting in 4 treatment discontinuations and 17 switches to another anti‐CGRP.

also in 5,682 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.